Palatin Technologies (PTN) Stock Price, News & Analysis

Company Overview

Palatin Technologies, Inc. (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization. Its pipeline has historically included multiple candidate programs at various stages of development, and the company has sought to progress those programs through clinical trials while evaluating potential collaborations to broaden development resources and market access.

Palatin operates in the United States and engages with the broader biopharma ecosystem to advance its products. Publicly traded on the NYSE American exchange, the company has worked to leverage scientific expertise and external partnerships to move assets forward. I do not have fully verifiable, up-to-date details on current executive leadership or recent corporate milestones; readers should consult the company’s filings and official releases for the latest leadership, pipeline and strategic information.

Key Stats

• Today's Range: $18.89 to $20.99
• 50-Day Range: $17.20 to $23.98
• 52-Week Range: $1.75 to $31.00
• Volume: 4,994 shs
• Average Volume: 16,248 shs
• Market Capitalization: $33.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

PTN Stock Analysis - Frequently Asked Questions

How have PTN shares performed this year?

Palatin Technologies' stock was trading at $15.38 on January 1st, 2026. Since then, PTN stock has increased by 22.9% and is now trading at $18.90.

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Palatin Technologies investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), 22nd Century Group (XXII), NVIDIA (NVDA) and Meta Platforms (META).

Company Calendar

• Today: 5/07/2026
• Next Earnings (Estimated): 5/19/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:PTN
• CIK: 911216
• Web: N/A
• Phone: (609) 495-2200
• Fax: 609-495-2202
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Palatin Technologies: $55.00
• High Price Target: $60.00
• Low Price Target: $50.00
• Potential Upside/Downside: +191.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.31 million
• Net Margins: N/A
• Pretax Margin: -107.40%
• Return on Equity: -5,516.91%
• Return on Assets: -114.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.76
• Quick Ratio: 2.76

Sales & Book Value

• Annual Sales: $4.49 million
• Price / Sales: 7.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.94) per share
• Price / Book: -3.83

Miscellaneous

• Outstanding Shares: 1,770,000
• Free Float: 1,646,000
• Market Cap: $33.45 million
• Optionable: N/A
• Beta: 0.63